MedTrace Logo

ED50 of Dexmedetomidine as an Adjuvant to 0.5% Hyperbaric Bupivacaine 12.5 mg for Spinal Anesthesia in Hip and Knee Surgery: An Up-and-Down Method Approach

NCT07144215 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-05

No results posted yet for this study

Summary

Determine ED50 dexmedetomidine adjuvant that can provide spinal anesthetic sensory blockade duration of 200 minutes on knee and pelvis surgery with up-and-down method.

Conditions

  • Knee Surgery
  • Pelvic Surgery
  • Spinal Aneshtesia

Interventions

DRUG

Dexmedetomidine 3 mcg

Patient received spinal injection of dexmedetomidine 3 mcg.

DRUG

Dexmedetomidine 4 mcg

Patient received spinal injection of dexmedetomidine 4 mcg.

DRUG

Dexmedetomidine 5 mcg

Patient received spinal injection of dexmedetomidine 5 mcg.

DRUG

Dexmedetomidine 6 mcg

Patient received spinal injection of dexmedetomidine 6 mcg.

DRUG

Bupivacain hyperbaric 0.5% 12.5 mg

Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07144215 on ClinicalTrials.gov